MarketPulse

continuous glucose monitoring

4 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Abbott Labs Stock Slides 22% on Weak Diagnostics, But Dividend Investors See Opportunity

$ABT down 22% after disappointing earnings, but strong medical devices and $21B Exact Sciences deal offer recovery potential for income seekers.
ABTEXAShealthcaredividend stock
GlobeNewswire Inc.GlobeNewswire Inc.··Senseonics Holdings, Inc.

Senseonics' Eversense 365 Proves Durable: Real-World Data Shows 94% Wear Rate, Strong Glucose Control

Senseonics reports real-world data from 5,059 Eversense 365 CGM users showing 93.8% wear time and strong glucose control metrics over one year.
SENSmedical devicediabetes management
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Surgical Robots and Glucose Monitors Positioned for Decade-Long Growth Despite Competition

Intuitive Surgical and DexCom positioned for long-term growth despite near-term competition, driven by aging populations and untapped market opportunities.
MDTDXCMISRGlong-term investinggrowth stocks
BenzingaBenzinga··Prnewswire

Global Diabetes Survey Reveals Market Gap: 80% Demand Predictive Tools Beyond CGM

Survey of 4,326 diabetics across 22 countries shows 80% demand predictive glucose forecasting tools, revealing unmet market need beyond current continuous glucose monitoring.
RHHBYhealthcare technologyType 1 diabetes